Details of the Drug
General Information of Drug (ID: DMSZ3T6)
Drug Name |
5-{8(Z),11(Z),14-pentadecatrienyl}resorcinol
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Cardol triene; CHEMBL459603; 5-(8Z,11Z,14-Pentadecatrienyl)resorcinol; 79473-24-8; CHEBI:52680; 5-(pentadeca-8,11,14-trien-1-yl)resorcinol; 5-[(8Z,11Z)-pentadeca-8,11,14-trien-1-yl]benzene-1,3-diol; (8Z,11Z)-5-(pentadeca-8,11,14-trien-1-yl)resorcinol; 5-pentadecatrienyl resorcinol; 5-{8(Z),11(Z),14-pentadecatrienyl}resorcinol; 5-((8Z,11Z)-pentadeca-8,11,14-trien-1-yl)benzene-1,3-diol; SCHEMBL2467234; MEGxp0_000811; ACon1_000596; DTXSID30872873; MolPort-001-740-965; 1,3-Benzenediol, 5-(8Z,11Z)-8,11,14-pentadecatrienyl-
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 2 | Molecular Weight (mw) | 314.5 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 7.2 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 12 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||